Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 189
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205085(US9556145, example 5 | methyl 3-chloro-2-(((3R,6R)...)
Affinity DataIC50: 11nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 11 | US9556145, example 10)
Affinity DataIC50: 11nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205088(US9556145, example 8 | methyl 3-fluoro-2-{[(3r,6r)...)
Affinity DataIC50: 24.9nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50084382(CHEMBL3426138 | US9556145, example 1)
Affinity DataIC50: 26nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205083(US9556145, example 3 | methyl 2-{[(3r,6r)-6- methy...)
Affinity DataIC50: 28nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205084(US9556145, example 4 | methyl 5-bromo-2- {[(3r,6r)...)
Affinity DataIC50: 28.9nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205086(US9556145, example 6 | dimethyl 2-{[(3r,6r)-6-meth...)
Affinity DataIC50: 30.8nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 11 | US9556145, example 10)
Affinity DataIC50: 31nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205083(US9556145, example 3 | methyl 2-{[(3r,6r)-6- methy...)
Affinity DataIC50: 57nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205084(US9556145, example 4 | methyl 5-bromo-2- {[(3r,6r)...)
Affinity DataIC50: 60nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205087(US9556145, example 7 | methyl 2-methyl-6-{[(3r,6r)...)
Affinity DataIC50: 82.6nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 11 | US9556145, example 10)
Affinity DataIC50: 96nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205089(US9556145, example 9 | methyl 2-{[(3r,6r)-1-{[6- m...)
Affinity DataIC50: 406nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205086(US9556145, example 6 | dimethyl 2-{[(3r,6r)-6-meth...)
Affinity DataIC50: 526nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 11 | US9556145, example 10)
Affinity DataIC50: 597nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205085(US9556145, example 5 | methyl 3-chloro-2-(((3R,6R)...)
Affinity DataIC50: 953nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50084382(CHEMBL3426138 | US9556145, example 1)
Affinity DataIC50: 1.40E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205087(US9556145, example 7 | methyl 2-methyl-6-{[(3r,6r)...)
Affinity DataIC50: 1.47E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205088(US9556145, example 8 | methyl 3-fluoro-2-{[(3r,6r)...)
Affinity DataIC50: 1.69E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205092(US9556145, example 12)
Affinity DataIC50: 2.11E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205089(US9556145, example 9 | methyl 2-{[(3r,6r)-1-{[6- m...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205092(US9556145, example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2018
Entry Details
Go to US Patent